Key Considerations for Selecting a Genomic Decision Support Platform for Implementing Pharmacogenomics
暂无分享,去创建一个
K. Gripp | P. Arn | V. Funanage | Benjamin Q Duong | Kathryn V Blake | Susan M Kirwin | Nathan D. Seligson | Kelsey J Cook | Katherine M. Robbins | Stephen T. Lawless | Mary M. Lee | David West | K. Blake
[1] Gil Alterovitz,et al. Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity , 2020, J. Am. Medical Informatics Assoc..
[2] Julie A. Johnson,et al. How to Transition from Single Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial. , 2020, Clinical pharmacology and therapeutics.
[3] Michelle Whirl-Carrillo,et al. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. , 2018, Pharmacogenomics.
[4] PJ Caraballo,et al. Electronic Medical Record‐Integrated Pharmacogenomics and Related Clinical Decision Support Concepts , 2017, Clinical pharmacology and therapeutics.
[5] J. Hoffman,et al. Integrating pharmacogenomics into electronic health records with clinical decision support. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[6] S. Chumnumwat,et al. Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges , 2016, Clinical and translational science.
[7] J. Peterson,et al. Clinician Perspectives on Using Pharmacogenomics in Clinical Practice. , 2015, Personalized medicine.
[8] Stephen T Lawless,et al. Time for Alert-ology or RE-sensitization? , 2013, Pediatrics.